Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7011 | Abn-CBD |
| Neurobehaviorally inactive cannabinoid that acts as a selective agonist for GPR55 (EC50 values are 2.5, >30 and >30 μM at GPR55, CB1 and CB2 receptors respectively). Increases phosphorylation of protein kinases in, and migration of, human umbilical vein endothelial cells. | |
| BCC7014 | Ciglitazone |
| Selective agonist at PPARγ (peroxisome proliferator-activated receptor γ). Activates PPARγ with an EC50 value of 3 μM in vitro, and is at least 33-fold selective over PPARα and δ. Antihyperglycemic in vivo. | |
| BCC7015 | PPNDS |
| Potent and selective P2X1 receptor antagonist (pKB = 7.43 in rat vas deferens). Up to 52-fold selective over P2Y1 receptors, and selective over ecto-nucleotidase, α1A-adrenoceptors, A1, A2B, H1 and M3 receptors. | |
| BCC7017 | MK 886 |
| An inhibitor of leukotriene biosynthesis (IC50 = 3 nM in human polymorphonuclear leukocytes). Acts by inhibiting 5-lipoxygenase-activating protein (FLAP) (IC50 = 30 nM for inhibition of [125I]-L-691,678 photoaffinity labelling). Also moderately potent PPARα antagonist (IC50 = 0.5-1 μM). Orally active in vivo. | |
| BCC7021 | RX 821002 hydrochloride |
| Potent, selective α2-adrenoceptor antagonist with very low affinity for imidazoline sites. Displays selectivity for the α2D over the α2A subtypes (pKd values are 9.7 and 8.2 respectively). | |
| BCC7022 | BADGE |
| PPARγ pure antagonist with micromolar affinity in 3T3-L1 and 3T3-F442A preadipocyte cells; selective over PPARδ and PPARα. Antagonizes the ability of rosiglitazone to stimulate transcriptional activity of PPARγ. Acts as a PPARγ agonist in an ECV304 cell line. Also produces PPARγ-independent apoptosis of tumor cells via several mechanisms. Active in vivo. | |
| BCC7026 | Arvanil |
| Cannabinoid CB1 and vanilloid TRPV1 (VR1) agonist (Ki values are 0.5 and 0.3 μM respectively). Also inhibits the anandamide transporter (IC50 = 3.6 μM). Analgesic, vasodilatory and anti-inflammatory in vivo. | |
| BCC7028 | MG 624 |
| A selective antagonist for neuronal α7 subunit- containing nAChR subtypes. Inhibits α-Bgtx binding to chick α7 and α4β2 subtypes with Ki values of 106 nM and 84 μM respectively. | |
